Drug intelligence / Profile preview

Fertitonex

Development stage: Unknown
Lead developer: INTEGRA Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Fertitonex is a multi-ingredient dietary supplement formulated to support male reproductive health and improve semen parameters. Developed by Nerhadou International, it is primarily indicated for men with clinical varicocele or idiopathic infertility characterized by poor sperm count, motility, or morphology (oligoasthenoteratozoospermia). The supplement contains a synergistic blend of antioxidants and micronutrients, including L-carnitine, acetyl-L-carnitine, coenzyme Q10, zinc, selenium, and essential vitamins such as C, E, B12, and folic acid. These components function by reducing oxidative stress in the seminal plasma and supporting mitochondrial energy production within sperm cells, which is critical for maintaining motility and DNA integrity.

Brand names: Fertitonex

Beyond the preview

Go deeper on Fertitonex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fertitonex.

Explore the full profile